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SUMMARY 
Some patients do not take medicines as they are supposed to. Our research showed that in Estonia 
one fifth of patients did not start treatment with osteoporosis medicines and only 20 percent used 
the medicines for at least three years as they should. This induces unnecessary costs to the 
healthcare system. 
ABSTRACT 
Purpose 
Medication non-adherence is the number one reason for not obtaining the expected clinical effect of 
medicines. With osteoporosis treatment it has been shown that both implementation of treatment 
and persistence influence the risk of fractures significantly. Long-term adherence to medication in 
Estonia is to be determined with this study. 
Methods  
A fifteen year retrospective study was carried out in order to establish initiation, implementation and 
persistence of Estonian patients. All new users of osteoporosis medicines were analyzed for all 
prescriptions they received during the study period. Sufficient adherence to treatment was defined 
as a patient being dispensed 80% or more prescribed doses for at least one year. 
Results 
The study period was from 2001 to 2015. 24,652 patients were included in the study. 93.7% 
(n=23,091) of the patients were women and 6.3% (n=1,564) were men. 4,636 (18%) patients were 
dispensed only one prescription. 44.2% of patients included in the study had medication possession 
ratio (MPR) ≥80% over follow-up period. 8,922 (36.2%) of all patients who were prescribed from 
2001 to 2015 persisted for 1 year with MPR≥80% and 19.8% persisted for 3 years. 40% of 
expenditure on osteoporosis medication was made for treatment courses with unsufficient 
adherence. 
Conclusions 
There is room for improvement in Estonia with medication adherence relating to all three aspects 
that determine adherence - initiation, implementation and persistence. This means further efforts 
are to be made to educate patients and healthcare professionals on realizing the importance of good 
adherence. 
KEYWORDS 
Osteoporosis; adherence; persistence; bisphosphonates; database. 
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1. INTRODUCTION 
Medication non-adherence is the number one reason for not obtaining the expected effect shown in 
clinical trials in real life [1] and it results in worsening of the disease and increased health care costs 
[2]. Adherence to medicines of chronic diseases comprises of three aspects: whether the patient 
initiates treatment, if he or she takes it as prescribed by the doctor and whether he or she persists 
with the treatment for a sufficient period of time [3]. 
Osteoporosis is a major health threat [4]. It alters bone architecture leaving them more fragile and 
more susceptible to fractures [5]. The main negative health outcome of fractures is loss of quality of 
life due to pain and disability caused by them [6]. Loss of bone mass itself is asymptomatic until a 
fracture occurs [7] and osteoporosis has clinical and public health relevance only because of the 
fractures [8]. The aging population and changes in people’s lifestyle result in a constant increase in 
the number of fractures all over the world [9]. Osteoporosis is a growing chronic health state in the 
Western world and is putting a significant load on both the individual and the society [10]. 
Effective pharmacological treatment options against osteoporosis are available (e.g. 
bisphosphonates, denosumab, strontium ranelate) [11]. With no single agent demonstrating 
superiority over another in preventing fractures [12]. Osteoporosis pharmacotherapy needs to be 
used for a longer period of time and patients need to adhere to treatment for it to be effective and 
cost-effective [11]. The number of patients who receive treatment within a year after a fragility 
fracture has been shown to be less than 20 % [13]. Half of the patients who receive the treatment 
adhere to it sufficiently and only 35% continue the treatment for at least a year [14].  
Improving adherence would effectively prevent more fractures [15] and healthcare resources could 
be spared by reducing finances spent on fragility fractures’ treatment [16]. Several factors have been 
shown to  influence adherence to medication but most important of those seem to be doctor-patient 
relationship,  patient awareness and co-payment of medicines [17, 18].  
The aim of our study was to establish adherence to osteoporosis medicines in Estonia and identify 
patient groups with poorer adherence so that future interventions may be targeted to improve 
adherence. We studied all three aspects of adherence - initiation, implementation and persistence. 
2. METHODS 
2.1 Setting and study cohort 
We use the term adherence to describe the combination of initiation of treatment, implementation 
of treatment and persistence with treatment. We studied each element of adherence separately and 
also provide results for all of them.  We considered sufficient theoretical medicines possession rate 
(MPR) of 80% or more during treatment. Osteoporosis medicines have demonstrated efficacy in 
clinical trials when taken at least for one year [19]. This could be considered a conservative estimate 
of sufficient persistence. Most of the efficacy trials have lasted for at least 3-years though [20–22]. 
Adherence in the context of our study was defined as a patient taking 80% or more of prescribed 
doses and persisting with treatment for one to three years. 
To establish adherence to osteoporosis medicines in Estonia we analyzed prescriptions dispensed 
from Estonian general pharmacies from 2001 to 2015. Pharmacy dispensing data has been shown to 
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be a valid proxy to assess patients’ medication adherence [23]. Prescription data were obtained from 
the Estonian Health Insurance Fund (EHIF) that keeps record of every dispensed prescription. 
Osteoporosis medications are reimbursed to all Estonian citizens with valid health insurance. 
Approximately 95% of the total population and all retired persons are insured in Estonia, so the study 
covered the vast majority of ambulatory drug consumption in Estonia [24].  
Patients aged 50 or above who were dispensed prescriptions with diagnosis codes M80 (osteoporosis 
with pathological fracture), M81 (osteoporosis without pathological fracture), M82 (osteoporosis in 
diseases classified elsewhere), M83 (adult osteomalacia), M84 (disorders of continuity of bone), M85 
(other disorders of bone density and structure) or Q78.8 (other congenital bone fragility) according 
to the tenth edition of the international classification of diseases (ICD-10) were included in the 
analysis. At least one of the diagnosis codes had to be present on at least one of the prescriptions for 
the patient to be included in the study. All prescriptions of one patient were identified by a unique 
identifier applied to each patient by EHIF. The actual identity of the patient was concealed from the 
researchers. For every prescription patient’s identifier, age, sex, diagnosis, specialty of the 
prescribing doctor, preparation and amount of packages dispensed was extracted. 
New users of osteoporosis medicines were eligible for our study. New users were defined as patients 
who had not been dispensed an osteoporosis medicines prescription for at least one year prior to the 
start of the study.  
Patients were followed up until they stopped treatment, until death or until the end of the study on 
the 31st of December 2015. 
2.2 Osteoporosis medicines 
Osteoporosis medicines used in Estonia are all classified in the anatomical therapeutic chemical (ATC) 
classification group M05B [25]. WHO defined daily dose (DDD) was used to calculate the number of 
days that the dispensed medicine would last a patient. For osteoporosis medicines the number of 
DDDs dispensed is a good predictor of treatment duration because the doses and dosing intervals do 
not differ between patients. We calculated the medication possession cumulatively meaning that 
with every prescription the number of DDDs dispensed was added to what the patient would have 
left from the previous prescriptions. 
2.3 Treatment gaps 
We also analyzed gaps in treatment or “drug holidays”. A period of 90 days or more when the 
already dispensed amount of medicines should have been depleted and a new prescription had not 
been dispensed was considered a gap. A gap longer than 180 days was considered an end of 
treatment course and if the patient was dispensed another prescription later in the study it was 
considered a new treatment course. 
2.4 Data analysis 
Analyses were undertaken using Stata v13 (StataCorp LP) and Joinpoint Regression Program, Version 
4.3.1.0. Joinpoint is statistical software for the analysis of trends using joinpoint models enabling to 
test if an apparent change in trend is statistically significant. Results are presented as average annual 
percent change (APC) over time period.  The tests of significance use a Monte Carlo Permutation 
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method [26]. Comparsion of adherent/non-adherent patients by background variables was done by 
logistic regression.  We considered statistically significant p-values less than 0.05. 
3. RESULTS 
3.1 Patients 
In total 25,480 new patients were identified who received osteoporosis medicines with at least one 
prescription during our study period. 825 of them were under 50 and were therefore left out of the 
study. Prescriptions of 3 patients were dispensed after the patient had died and these patients were 
also left out. 24,652 patients were included in the study. 93.7% (n=23,091) of the patients were 
women and 6.3% (n=1,564) were men. Age distribution of patients is presented in figure 1. 
3.2 Initiation of treatment 
Out of the 24,652 patients who started treatment with osteoporosis medicines 4,636 (18%) were 
dispensed only one prescription. The number of patients starting treatment was growing steadily 
from 2001 to 2009 and declined from 2010 to 2015. The increase was on average 17.7% per year and 
the decrease 13.0% per year. Both trends of change are statistically significant. The percent of 
patients who were dispensed only one prescription showed a statistically significant 2.4% annual 
increase throughout the study (figure 2). 
3.3 Implementation of treatment 
Overall 44.2% of patients included in the study had MPR ≥80% throughout their follow-up period. 
18.8% of patients were dispensed only one prescription and for these patients we did not calculate 
MPR. 37.0% of patients had MPR less than 80%. The percent of patients who had MPR over 80% 
showed an increasing trend during our study period. Out of the patients who initiated treatment in 
the beginning of 2000s around 60 to 70 percent were not implementing treatment sufficiently but 
only 20 to 30 percent of patients who started treatment towards the end of the study were not 
implementing the treatment (figure 3). The increase of patients with MPR≥80% can be divided into 
two periods - from 2001 to 2005 and from 2005 onward. Initially the annual increase of patients with 
MPR ≥80% was 29% and later it was 5%. 
3.4 Persistence with treatment 
Of the 24,652 patients who were included in our study 8,922 (36.2%) had MPR ≥80% and had a 
treatment course that lasted for at least 1 year. Only 19.8% of the patients persisted with treatment 
for at least 3 years with MPR≥80%. There were also almost 300 patients (n=299) who persisted with 
osteoporosis treatment with good implementation for longer than 10 years (figure 4). 
3.5 Gaps and restarters 
As our study period was very long patients who started treatment early in the study could stop 
treatment at some point and then start again after a while. They could also take smaller “drug 
holidays” during treatment. 2,483 patients had such “drug holidays” during their treatment. 4,555 
patients restarted treatment after stopping and 2,360 patients had “drug holidays” and they also 
restarted treatment. 47.0% of the patients who were dispensed medicines with at least 2 
prescriptions had shorter or longer gaps in their treatment. 17,737 patients (72.0%) started 
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treatment only once during the study but 4,636 of these patients were dispensed only one 
prescription. 19.5% of patients started osteoporosis treatment twice and 8.5% had 3 or more 
initiations of treatment. 2 patients restarted treatment 9 times during our 15-year study. 
3.6 What drives adherence 
Patient characteristics that determine medication adherence are presented in table 1. Women are 
2.4-times more likely (p<0.001) to have a treatment course longer than one year with MPR≥80% than 
men. The age of patients is statistically related with the probability of one being adherent for at least 
a year. Compared with patients aged 50-59 the probability increases for the age group 60-69 by 20% 
(p<0.001) and for 70-79 by 12% (p=0.004) but decreases with older patients. The results are similar if 
we look at 3-year persistence. Patients who had a fracture when starting treatment (ICD-code M80) 
were more likely to have good implementation and persist with treatment than those who did not 
have a fracture (ICD-code M81). When treatment was started by general practitioner adherence was 
lower than when treatment was started by specialist doctors. Using more than one different 
medicinal product or active substance from ATC group M05B increased the probability of having a 
treatment course with MPR≥80% that lasted at least for one year. 
3.7 Expenditure on medication 
In total 14,172,142€ was spent on osteoporosis medicines of patients who started treatment during 
our study period in Estonia. 8,247,370€ was spent by the Estonian Health Insurance Fund and 
6,647,697€ out-of-pocket by patients. Of the 14 million 8,471,773€ was spent on treatment of 
patients who had MPR≥80% and persisted for at least one year. 5,700,369€ was spent on treatment 
of patients who had MPR<80%, who persisted for less than a year or who were dispensed medicines 
with only one prescription.  
4. DISCUSSION 
4.1 Initiation 
In the beginning of our study the number of new patients who received osteoporosis therapy for the 
first time increased very quickly reached its peak in 2009 and then started decreasing. The increase is 
probably due to the drugs becoming more affordable to patients with EHIF providing bigger 
reimbursement and generic medicines coming to the market [24]. The major decline of new users is 
unexplained though, as the number of patients in Estonia receiving osteoporosis treatment cannot 
be regarded as sufficient [25]. Also the number of patients who were dispensed only one prescription 
has not decreased as would be expected when medicines become cheaper. It has rather increased 
indicating that affordability is not the main factor hindering initiation in Estonia. Aspects that do 
influence initiation need further clarification to plan for effective interventions to enhance initiation.  
4.2 Implementation 
MPR≥80% is considered optimal for osteoporosis treatment to be effective [27]. Overall 44.2% of 
patients in our study achieved this for at least one of their treatment courses. This is a rather poor 
result for osteoporosis treatment as implementation percentages have been reported from 46% [28] 
to even 94.6% [29]. Lower implementation percentages have been reported when using daily dosing 
regimens which have been shown to provide lower implementation [30] and on the other hand 
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higher implementation have been achieved while looking at the implementation of persistent 
patients which is bound to provide better results as patients who are mindful about taking their 
medicines for a longer period of time do so probably more orderly than patients overall. 44.2% of 
patients having MPR≥80% is one of the lowest percentages shown in adherence studies but this is 
probably because of our very long study period and including every new patient in the study. Other 
studies usually have shorter durations [31] and new patients typically have poorer adherence [32]. It 
is shown that during a treatment course of one to two and a half years not implementing the 
treatment can increase pooled fracture risk by up to 46% [31]. This means that there is a great 
number of patients in higher risk of fracture in Estonia despite the fact they are prescribed 
osteoporosis medicines. The quick increase of patients taking more than 80% of their medicines in 
the beginning of the study might be related to the increasing use of once weekly medicines and 
decreasing use of once daily medicines in the middle of the 2000s in Estonia. Once weekly medicines 
have been shown to have better adherence than once daily medicines [33]. Patients taking “drug 
holidays” also needs to be addressed while improving adherence as almost half of the patients had 
gaps in their treatment and it has been suggested that focusing on the reduction of gaps might have 
greater influence on overall adherence than improving MPR of patients who are on treatment [34]. 
4.3 Persistence 
Usually 1-year persistence is used to illustrate the duration of treatment. In our study 36.2% of 
patients continued treatment for at least a year and 19.8% for three years with MPR≥80%. In earlier 
studies 1-year persistence has been reported in a wide range of 18%-75%. The variation is driven by 
the different methods used in the studies (data-derived persistence and self-report etc.) [35]. But as 
with implementation - analyzing all new patients long-term is bound to give poorer results of 
adherence. It has been shown that 3-year persistence may reduce the risk of fractures by 41% 
compared to 1-month persistence [36]. This means that interventions to improve persistence are 
also needed in Estonia and that long-term persistence to treatment of new patients might be even 
lower than suggested before in similar studies. 
4.4 Factors that influence adherence 
Several patient characteristics have been shown before to predict poorer adherence [37] and our 
study was no different. First of all men tended to have poorer adherence in our study compared to 
women. This is not unexpected as men have been shown before to be less adherent [38]. As the 
proportion of men taking osteoporosis medicines is very small (6.3% of men in our study) tackling 
men separately to improve their adherence would probably not give a population wide health 
benefit. 
There is some co-variance between the effects of patients’ age, existent fracture and the prescribing 
doctor on adherence. All of these factors showed significant influence on adherence but as older 
people have more fractures and patients with fractures tend to put on treatment by specialist 
doctors rather than their GP then the patients decision to take ones medicine or not might come 
down to whether a patient has a fracture or not, as having a prior fracture motivates patients to take 
their medicines as prescribed [39]. Whether patient can afford their medicines is also a driver for 
adherence [40]. In Estonia the reimbursement percentage increases at the age of 63 from 75% to 
90%. This could explain the higher adherence in the age groups above 60 compared to the group of 
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50 – 59. Higher reimbursement for osteoporosis medicines was established in the mid-2000s in 
Estonia. Before 2007 osteoporosis drugs were reimbursed with 50% by EHIF.  
A bit unexpected for us was the result that the number of different medical products with the same 
active substance used by the patient did not have a negative effect on adherence. This could mean 
that generic substitution can be carried out without concern in Estonia and the patient can have the 
cheapest alternative offered to them. There has been concern in Estonia amongst the general public 
about generic substitution with a preparation containing the same active substance but our study 
indicates that what comes to osteoporosis treatment these concerns do not affect patients’ 
medication adherence. 
4.5 Expenditure 
Medicines are expensive and national health systems are constantly working with constrained 
budgets. Poor adherence to osteoporosis medication has been shown to lead to significant waste of 
money and avoidable fractures [41]. Our study showed that up to 40% of the expenditure on 
osteoporosis medication might not have served its purpose because patients did not adhere to 
treatment. This could also influence the cost-effectiveness of medicines as the health benefits we 
assume from clinical trials are most likely not achieved in every day practice. In addition costs of 
hospitalization and other medical services have been shown to increase with poor adherence 
[42].This is also underpinning the importance of improving adherence as otherwise we are putting an 
even bigger pressure on the health system and the money spent in vain might restrict access to 
newer medicines. 
4.6 Strengths 
The studies of patient behavior are important for the development of medicines’ policies and 
reimbursement systems but also as feedback to doctors and patients. The main strength of our study 
is the duration of the study. Fifteen year adherence studies have hardly ever done before [31] and 
studies lasting one to two years are already considered long-term. All osteoporosis medicines are 
prescription only and our study covers over 95% of Estonian population making it a representative 
study of our actual adherence situation because of full coverage.  
4.7 Limitations 
Our study also has some limitations. Most and foremost as we looked at dispensing data we cannot 
know whether the patient actually consumed the medicines they bought from the pharmacy. We 
make the assumption that every pill that is dispensed from the pharmacy is also consumed but this 
surely is not the actual case. This is a common issue with adherence assessment though as 
medication event monitoring systems are seldom used in real life adherence studies.  We also could 
not assess whether the prescribing of osteoporosis medicines was justified in every single case and if 
the patients where in fact in need for long-term therapy. The reasons why patients stop taking their 
medication cannot be analyzed using databases but the actual reasons could provide us with the 
most valuable information on how to approve adherence. 
5. CONCLUSIONS 
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There is room for improvement in Estonia with medication adherence relating to all three aspects 
that determine adherence. 18% of patients were dispensed only one prescription, 44.2% of patients 
had MPR≥80%, 36.2% of patients persisted with treatment for a year and only 19.8% three years or 
more with good implementation. Around 40% of the expenditure on osteoporosis medication 
probably would not result in the clinical effect aimed for as it was spent on non-adherent treatment 
courses. 
This means further efforts are to be made to educate patients and healthcare professionals on the 
importance of good adherence to antiosteoporotic treatment in order to gain the clinical 
effectiveness offered by these drugs but that is not achieved with poor adherence to treatment. 
Further research should be done to pin point the reasons for not initiating, implementing or 
persisting with medication and evaluate the potential regional differences of adherence in Estonia to 
better target interventions. 
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7. TABLES 
Table 1. Factors relating to the probability of having MPR≥ 80% for at least 1 year or 3 years 
  
  
MPR ≥ 80% for at least 1 
year  
(OR, CI95%, p-value) 
MPR ≥ 80% for at least 3 
years  
(OR, CI95%, p-value) 
Sex 
male 1 1 
female 2.37 (2.09-2.69)  p<0.001 2.72 (2.28-3.25) p<0.001 
Age in years 
50-59 1 1 
60-69 1.20 (1.11-1.30)  p<0.001 1.29 (1.18-1.43)  p<0.001 
70-79 1.12 (1.04-1.21) p=0.004 1.18 (1.07-1.30)  p=0.001 
80-89 0.89 (0.80-0.98) p=0.014 0.77 (0.69-0.88)  p<0.001 
90-… 0.45 (0.29-0.70)  p<0.001 0.18 (0.07-0.44)  p<0.001 
Diagnosis 
M80 1 1 
M81 0.87 (0.83-0.92) p<0.001 0.86 (0.81-0.92)  p<0.001 
Doctors’ speciality 
General 
Practitioner 
1 1 
Orthopedist 1.13 (1.02-1.26)  p=0.018 0.97 (0.86-1.11)  p=0.696 
Rheumatologist 1.47 (1.38-1.56)  p<0.001 1.33 (1.24-1.43)  p<0.001 
Other 0.88 (0.80-0.96)  p=0.003 0.87 (0.78-0.96)  p=0.009 
Number of different 
preparations 
dispensed 
For every 
additional 
medicinal 
product  
1.91 (1.86-1.97)  p<0.001 2.24 (2.17-2.31)  p<0.001 
Number of different 
active substances 
dispensed 
For every 
additional 
active 
substance 
2.05 (1.97-2.13) p<0.001 2.46 (2.36-2.57)  p<0.001 
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8. FIGURES 
 
Fig. 1 Age distribution of patients starting treatment with osteoporosis medication (ATC group M05B) 
in Estonia in 2001-2015. 
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Fig. 2 The yearly number of patients who started treatment with osteoporosis medication and the 
modelled trends of all starting patients and those patients who were dispensed only one 
prescription. 
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Fig. 3 The implementation of osteoporosis treatment in Estonia according to the year the treatment 
was initiated. Data presented as percent of patients who had medication possession ratio (MPR) 
≥80%, under 80%, who were dispensed only one prescription and the modelled annual change in the 
percentage of patients with MPR≥80%. 
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Fig. 4 The percent of patients persisting with treatment with MPR≥80% after a given number of years 
 
 
